4 recent biologics treatments under development

Eric Oliver -   Print  |
Listen

Here are four treatments that are in development in the biologics space:

Grünenthal and Mesoblast entered into a partnership to develop a biologics-based treatment for chronic lower back pain.

NervGen Pharma is planning its clinical development strategy for its compound, NVG-291, in spinal cord injury and multiple sclerosis patients.

Duchenne UK awarded researchers from Minneapolis-based University of Minnesota Medical School $945,000 to advance their work around a stem cell-based therapy to treat Duchenne muscular dystrophy.

Ortho Regenerative Technologies reported a successful pre-investigational drug meeting with the FDA in February and is now preparing for its rotator cuff phase I/II clinical trial.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers